Federal judge rejects Merck's constitutional challenge to Medicare drug price negotiation
Judge Colleen Kollar-Kotelly of the US District Court for the District of Columbia rejected Merck's First and Fifth Amendment challenge to the Inflation Reduction Act's Medicare drug price negotiation programme. Merck filed the first industry challenge to the programme in June 2023.
A federal judge in Washington, DC rejected Merck & Co.'s constitutional challenge to the Medicare drug price negotiation programme on August 24, 2026, more than three years after the company became the first drugmaker to sue over it. Judge Colleen Kollar-Kotelly found that Merck had failed to show that the programme compels speech in violation of the First Amendment or takes private property without just compensation in violation of the Fifth Amendment.
The Inflation Reduction Act of 2022 authorised the Centers for Medicare & Medicaid Services to negotiate prices directly with manufacturers for certain high-cost drugs without generic competition. Merck filed suit on June 6, 2023, arguing that the scheme used severe penalties to force manufacturers to sell patented medicines below their value, amounting to a taking, and that requiring companies to sign agreements accepting government-set prices compelled them to endorse a message they rejected. Merck's diabetes drug Januvia was among the first ten drugs selected for negotiation. Judge Kollar-Kotelly held that manufacturers are free to decide whether to participate in the programme, a finding that undercut both constitutional claims.
Patients for Affordable Drugs, an advocacy group, welcomed the decision and said the industry had spent years and millions of dollars on arguments that had repeatedly failed in court.
The ruling extends a long run of defeats for manufacturers challenging the programme. Five days earlier, a Maryland judge dismissed a second AstraZeneca suit. In May 2026 the Supreme Court declined to hear challenges brought by Johnson & Johnson, Bristol Myers Squibb, Novo Nordisk, Novartis, Boehringer Ingelheim and AstraZeneca. AbbVie filed suit in February 2026 challenging the selection of Botox for the third negotiation cycle, and a challenge brought by PhRMA over the first cycle was pending.
Merck had not publicly confirmed whether it will appeal. With the Supreme Court having turned away the earlier petitions, health policy commentators have pointed to the remaining cases, including those brought by AbbVie and PhRMA, as the most likely route to a circuit split that could bring the programme back before the justices.
Cite this report
The Precedent. "Federal judge rejects Merck's constitutional challenge to Medicare drug price negotiation." August 22, 2026. https://theprecedent.org/article/federal-judge-rejects-mercks-constitutional-challenge-to-medicare-drug-price-neg
